---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-157512"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2022-05-23T23:59:59+00:00"
generated_at: "2026-06-25T08:19:38.412469+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MindMed appoints Schond Greenway as CFO, effective May 23, 2022

## Summary
- Schond Greenway named CFO effective May 23, 2022; previously CFO at Avalo Therapeutics.
- Base salary of $400,000; eligible for discretionary annual cash bonus with 40% target.
- Received option for 1,650,000 shares (4-yr vest) and RSU for 1,270,000 shares (4-yr vest).
- Greenway brings experience from Avalo, Mesoblast, Halozyme, and investment banks.

## SEC filing metadata
- accession: 0001193125-22-157512
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2022-05-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000119312522157512/0001193125-22-157512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000119312522157512/d320568d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-157512
- JSON: https://secwatch.observer/filing/0001193125-22-157512.json
- Plain text: https://secwatch.observer/filing/0001193125-22-157512.txt

## Key facts
- Executive change
  Schond Greenway was appointed as Chief Financial Officer at Definium Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 23, 2022, Mind Medicine (MindMed) Inc. (the “Company”) announced the appointment of Schond Greenway as the Company’s Chief Financial Officer, effective May 23, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000119312522157512/0001193125-22-157512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.